CD38 and Miyoshi myopathy: Daratumumab, an anti-CD38 mAb for the treatment of MM, targets CD38-overexpressing MM and immunosuppressor cells, including regulatory T and B cells (Tregs and Bregs) and myeloid-derived suppressor cells (MDSCs), killing these cells by antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) [68].